As an organic chemist and a scientist interested in psychedelics, particularly MDMA, I’ve always been fascinated by the concept of homochirality. This phenomenon, where molecules like amino acids and sugars exist predominantly in one chiral form, is fundamental to both nature and drug design.
A recent article by Ozturk and Sasselov provides an insightful overview of homochirality, exploring why natural amino acids are homochiral and how nature has chosen this pathway:
On the origins of life’s homochirality: Inducing enantiomeric excess with spin-polarized electrons.
The ACS YouTube video is excellently designed to explain the importance of stereoselectivity in drugs, highlighting examples such as L-dopa, but there are more examples like thalidomide, and MDMA.
In my recent research, my coauthors and I investigated deeply into the effect of stereospecificity on MDMA activity, exploring how the different enantiomers of this compound can have vastly different effects on the human brain:
• Uncovering Structure–Activity Relationships of Phenethylamines: Paving the Way for Innovative Mental Health Treatments
• Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder
Understanding the stereospecificity of MDMA not only enhances our knowledge of its pharmacological properties but also has significant implications for its therapeutic use. This researches underscore the importance of considering chirality in drug design and development, ensuring that we harness the full potential of these compounds for therapeutic purposes.
Considering the recent denial by the FDA against using MDMA as a treatment, I personally believe that focusing more on MDMA enantiomers may enhance its therapeutic potential. We are preparing to submit a new publication soon, which includes fascinating new SAR data about the effect of chirality on psychedelic compounds.
Let’s see what the future holds!
#OrganicChemistry #Psychedelics #MDMA #Chirality #DrugDesign #Pharmaceuticals #Research
L-DOPA is the best drug we have for Parkinson’s disease, but its molecular mirror image, D-DOPA, causes dangerous side effects. Making L-DOPA without D-DOPA is surprisingly hard, and requires a specific kind of molecule to pull off. But getting that specific molecule requires, another, different and equally specific molecule, and so on, and so on.
In this video, host George Zaidan explains how Bill Knowles, who received the 2001 #NobelPrize in Chemistry for this feat, pulled it off, and why “chiral synthesis”, as it’s called, is really just turtles all the way down.
Watch on YouTube: https://lnkd.in/erS5rvq5
#ParkinsonsDisease #ChemNobel #DrugSynthesis #PharmaceuticalChemistry
Founder at Argento Studios, Journalism expert in social media.
3moLove this brand